Strober Bruce E, Siu Kimberly, Alexis Andrew F, Kim Gene, Washenik Ken, Sinha Animesh, Shupack Jerome L
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA.
J Am Acad Dermatol. 2005 Jun;52(6):1082-4. doi: 10.1016/j.jaad.2005.03.039.
In this prospective, open-label pilot study, we evaluated the safety and efficacy of etanercept, a TNF-alpha inhibitor, in the treatment of moderate to severe alopecia areata, alopecia totalis, or alopecia universalis. Seventeen otherwise healthy adults with moderate to severe alopecia areata were enrolled. The primary outcome measure was the extent of hair regrowth during and after the end of treatment as evaluated by the Severity of Alopecia Tool (the SALT score). After between 8 and 24 weeks of continuous treatment with etanercept 50 mg given subcutaneously twice weekly, significant regrowth of hair was not shown in any of the subjects treated. Based on these results, etanercept appears to be ineffective in treating subjects with treatment-refractory, moderate to severe alopecia areata, alopecia totalis, or alopecia universalis.
在这项前瞻性、开放标签的试点研究中，我们评估了肿瘤坏死因子-α抑制剂依那西普治疗中度至重度斑秃、全秃或普秃的安全性和疗效。纳入了17名患有中度至重度斑秃的其他方面健康的成年人。主要结局指标是通过脱发严重程度工具（SALT评分）评估治疗期间及治疗结束后的毛发生长程度。在用依那西普50mg皮下注射每周两次连续治疗8至24周后，接受治疗的任何受试者均未出现明显的毛发生长。基于这些结果，依那西普似乎对治疗难治性中度至重度斑秃、全秃或普秃患者无效。
